With over 35 years of experience in the pharmaceutical industry, Stephan Fritschi has stepped into his new role as CEO of CARBOGEN AMCIS with a clear vision: to build on the company’s legacy of scientific excellence while embracing transformation.
In a recent in-depth interview, Stephan outlined his strategic focus for the future: operational excellence, long-term partnerships, and a people-centric approach that puts employee engagement at the heart of the business. His leadership marks an exciting chapter for the CDMO, known for its expertise in highly potent APIs and sterile drug product manufacturing.
One key milestone in the company’s ongoing development is the Saint-Beauzire facility in France, which recently secured GMP certification following a successful ANSM inspection. This significant achievement reinforces CARBOGEN AMCIS’s commitment to quality and regulatory excellence in aseptic drug product manufacturing.
For specialists across the pharma and biotech space — from API innovators to commercial-scale manufacturers — Fritschi’s priorities align with industry imperatives: capacity optimisation, continuous investment in capabilities, and driving value beyond cost through collaborative innovation.
A full interview is now available. Discover how Stephan Fritschi plans to shape the future of CARBOGEN AMCIS.
Read the full interview on our website.
